The substrate domain of BCAR1 is essential for anti-estrogenresistant proliferation of human breast cancer cells

Breast Cancer Research and Treatment

Volumn 120, Issue 2, 2010, Pages 401-408

  Brinkman, Arend ^a   De Jong, Danielle ^a   Tuinman, Sietske ^a   Azaouagh, Najat ^a   Van Agthoven, Ton ^a   Dorssers, Lambert C J ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

Adaptor proteins; Chimerical proteins; Endocrine therapy; Fulvestrant; Tamoxifen resistance

Indexed keywords

ANTIESTROGEN; CELL PROTEIN; COMPLEMENTARY DNA; CRK ASSOCIATED SUBSTRATE PROTEIN; PROTEIN HEF1; PROTEIN SH3; TAMOXIFEN; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; BREAST CANCER; CANCER RESISTANCE; CARBOXY TERMINAL SEQUENCE; CELL GROWTH; CONTROLLED STUDY; DRUG TREATMENT FAILURE; GENETIC SCREENING; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CRK-ASSOCIATED SUBSTRATE PROTEIN; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; PHOSPHOPROTEINS; PROTEIN STRUCTURE, TERTIARY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAMOXIFEN;

EID: 77950690680     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0403-4     Document Type: Article

References (50)

1. 1. Group Early Breast Cancer Trialists' Collaborative (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717 (Pubitemid 40719106)
2. Jaiyesimi IA, Buzdar AU, Decker DA et al (1995) Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13:513-529
3. 3. Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combating resistance, Nat Rev Cancer 2:101-112 (Pubitemid 37328797)
4. 4. Clarke R, Liu MC, Bouker KB et al (2003) Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22:7316-7339 (Pubitemid 37492898)
5. 5. Osborne CK, Shou J, Massarweh S et al (2005) Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11:865s-870s (Pubitemid 40111098)
6. 6. Lewis JS, Jordan VC (2005) Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res 591:247-263 (Pubitemid 41654853)
7. Riggins RB, Schrecengost RS, Guerrero MS et al (2007) Pathways to tamoxifen resistance. Cancer Lett 256:1-24
8. 8. Dorssers LCJ, Van Agthoven T, Dekker A et al (1993) Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: identification of bear-1, a common integration site. Mol Endocrinol 7:870-878 (Pubitemid 23220637)
9. Van Agthoven T, Veldscholte J, Smid M et al (2009) Functional screen identifies genes associated with human breast cancer progression. Breast Cancer Res Treat 114:23-30
10. 10. Sakai. R, Iwamatsu A, Hirano N et al (1994) A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phosphorylation- dependent manner. EMBO J 13:3748-3756 (Pubitemid 24275020)
11. Sakai R, Iwamatsu A, Hirano N et al (1994) Characterization, partial purification, and peptide sequencing of p130, the main phosphoprotein associated with v-Crk oncoprotein. J Biol Chem 269:32740-32746
12. Brinkman A, Van der Flier S, Kok EM et al (2000) BCAR1, a human homologue of the adapter protein p 130 Cas and antiestrogen resistance in breast cancer cells. J Natl Cancer Inst 92:112-120
13. Ta HQ, Thomas KS, Schrecengost RS et al (2008) A novel association between p130 Cas and resistance to the chemotherapeutic drug adriamycin in human breast cancer cells. Cancer Res 68:8796-8804
14. 14. Van der Flier S, Brinkman A, Look MP et al (2000) Bcarl/ p130 Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. J Natl Cancer Inst 92:120-127 (Pubitemid 30089868)
15. Van der Flier S, Van der Kwast TH, Claassen CJC et al (2001) Immunohistochemical study of the BCAR1/p130Cas protein in non-malignant and malignant human breast tissue. Int J Biol Markers 16:172-178
16. Van der Flier S, Chan CMW, Brinkman A et al (2000) BCAR1/ p130 Cas expression in untreated and acquired tamoxifen-resistant human breast carcinomas. Int J Cancer 89:465-468
17. 17. Grebenchtchikov N, Brinkman A, Van Broekhoven SPJ et al (2004) Development of an ELISA for measurement of BCAR1 protein in human breast cancer tissue. Clin Chem 50:1356-1363 (Pubitemid 38970642)
18. 18. Dorssers LCJ, Grebenchtchikov N, Brinkman A et al (2004) The prognostic value of BCAR1 in patients with primary breast cancer. Clin Cancer Res 10:6194-6202 (Pubitemid 39287526)
19. 19. O'Neill GM, Fashena SJ, Golemis EA (2000) Integrin signalling: a new cas(t) of characters enters the stage. Trends Cell Biol 10: 111-119 (Pubitemid 30110694)
20. Bouton AH, Riggins RB, Bruce-Staskal PJ (2001) Functions of the adapter protein Cas: signal convergence and the determination of cellular responses. Oncogene 20:6448-6458
21. 21. Singh MK, Dadke D, Nicolas E et al (2008) A novel Cas family member, HEPL, regulates FAK and cell spreading. Mol Biol Cell 19:1627-1636 (Pubitemid 351805115)
22. 22. Cabodi S, Moro L, Baj G et al (2004) p130Cas interacts with estrogen receptor alpha and modulates non-genomic estrogen signaling in breast cancer cells. J Cell Sci 117:1603-1611 (Pubitemid 38559834)
23. 23. Defilippi P, Di Stefano P, Cabodi S (2006) p130 Cas: a versatile scaffold in signaling networks, Trends Cell Biol 16:257-263 (Pubitemid 43728873)
24. Riggins RB, Thomas KS, Ta HQ et al (2006) Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer Res 66:7007-7015
25. Cabodi S, Tinnirello A, Di Stefano P et al (2006) p130 Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cancer Res 66:4672-4680
26. 26. Honda H, Oda H, Nakamoto T et al (1998) Cardiovascular anomaly, impaired actin bundling and resistance to Src- induced transformation in mice lacking p130 Cas. Nat Genet 19:361-365 (Pubitemid 28357908)
27. 27. Kim M., Gans JD, Nogueira C et al (2006) Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125:1269-1281 (Pubitemid 43949521)
28. 28. O'Neill GM, Seo S, Serebriiskii IG et al (2007) A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9. Cancer Res 67:8975-8979 (Pubitemid 47535876)
29. 29. Singh M, Cowell L, Seo S et al (2007) Molecular basis for HEF1/ NEDD9/Cas-L action as a multifunctional co-ordinator of invasion, apoptosis and cell cycle. Cell Biochem Biophys 48:54-72 (Pubitemid 47345633)
30. Cas to SH2 and SH3 domains of Src kinase. J Biol Chem 271:8959-8965
31. Burnham MR, Bruce-Staskal PJ, Harte MT et al (2000) Regulation of c-SRC activity and function by the adapter protein CAS. Mol Cell Biol 20:5865-5878
32. 32. Ruest PJ, Shin NY, Polte TR et al (2001) Mechanisms of CAS substrate domain tyrosine phosphorylation by FAK and Src. Mol Cell Biol 21:7641-7652 (Pubitemid 32988775)
33. Sharma A, Mayer BJ (2008) Phosphorylation of p130 Cas initiates Rae activation and membrane ruffling. BMC Cell Biol 9:50
34. 34. Shen Y, Jia Z, Nagele RG et al (2006) SRC uses Cas to suppress Fhll in order to promote nonanchored growth and migration of tumor cells. Cancer Res 66:1543-1552 (Pubitemid 43259936)
35. 35. Shen Y, Khusial PR, Li X et al (2007) SRC utilizes Cas to block gap junctional communication mediated by connexin43. J Biol Chem 282:18914-18921 (Pubitemid 47100169)
36. 36. Patwardhan P, Shen Y, Goldberg GS et al (2006) Individual Cas phosphorylation sites are dispensable for processive phosphorylation by Src and anchorage-independent cell growth. J Biol Chem 281:20689-20697 (Pubitemid 44115411)
37. 37. Cai D, Clayton LK, Smolyar A et al (1999) AND-34, a novel p130 Cas-binding thymic stromal cell protein regulated by adhesion and inflammatory cytokines. J Immunol 163:2104-2112 (Pubitemid 29382216)
38. 38. Cai D, Iyer A, Felekkis KN et al (2003) AND-34/BCAR3, a GDP exchange factor whose overexpression confers antiestrogen resistance, activates Rac, PAK1, and the cyclin D1 promoter. Cancer Res 63:6802-6808 (Pubitemid 37322962)
39. Gotoh T, Cai D, Tian X et al (2000) p130 Cas regulates the activity of AND-34, a novel RaI, Rap 1, and R-Ras guanine nucleotide exchange factor. J Biol Chem 275:30118-30123
40. Riggins RB, Quilliam LA, Bouton AH (2003) Synergistic promotion of c-Src activation and cell migration by Cas and AND34/BCAR3. J Biol Chem 278:28264-28273
41. Schrecengost RS, Riggins RB, Thomas KS et al (2007) Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130 Cas membrane localization and membrane ruffling. Cancer Res 67:6174-6182
42. 42. Van Agthoven T, Van Agthoven TLA, Dekker A et al (1998) Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells. EMBO J 17:2799-2808 (Pubitemid 28227126)
43. Van Agthoven T, Van Agthoven TLA, Portengen H et al (1992) Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. Cancer Res 52:5082-5088
44. Law SF, Zhang YZ, Klein-Szanto AJP et al (1998) Cell cycleregulated processing of HEF1 to multiple protein forms differentially targeted to multiple subcellular compartments. Mol Cell Biol 18:3540-3551
45. Riggins RB, De-Berry RM, Toosarvandani MD et al (2003) Src-Dependent Association of Cas and p85 Phosphatidylinositol 3′-Kinase in v-crk-Transformed Cells. Mol Cancer Res 1:428-437
46. Pawson T (1995) Protein modules and signalling networks, Nature 373:573-580
47. Garron ML, Arsenieva D, Zhong J et al (2009) Structural insights into the association between BCAR3 and Cas family members, an atypical complex implicated in Anti-oestrogen resistance. J Mol Biol 386:190-203
48. cas-like docking protein, associates with focal adhesion kinase and induces pseudohyphal growth in Sacchawmyces cerevisiae. Mol Cell Biol 16:3327-3337
49. Van Agthoven T, Sieuwerts AM, Meijer-Van Gelder ME et al (2009) Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol 27:542-549
50. 50. Nasertorabi F, Tars K, Becherer K et al (2006) Molecular basis for regulation of Src by the docking protein pl30Cas. J Mol Recognit 19:30-38 (Pubitemid 43129784)